Therapeutic use of P75NTR neurotrophin binding protein
Disclosed herein are therapeutic uses of p75NTR neurotrophin binding proteins and related molecules, such as fusion proteins comprising p75NTR neurotrophin binding proteins and immunoglobulin Fc or portions thereof, in the treatment of osteoarthritis.
1 . A pharmaceutical composition, comprising an amount of the polypeptide of SEQ ID NO: 3 and a pharmaceutically acceptable carrier, an excipient, or a combination thereof, wherein the amount is an amount effective to treat osteoarthritis or to slow, arrest, or reverse progression of osteoarthritis in a mammalian subject suffering therefrom, and wherein the amount comprises a dose of between 0.3-3.0 mg/kg body weight.
2 . The pharmaceutical composition of claim 1 , wherein to treat osteoarthritis comprises:
a. reduction in cartilage loss;
b. regrowth of cartilage;
C. increase in joint mobility;
d. curative treatment; or
e. any combination thereof.
3 . The pharmaceutical composition of claim 2 , wherein progression of osteoarthritis is determined by the rate of cartilage loss or regrowth.
4 . The pharmaceutical composition of claim 1 , wherein the polypeptide of SEQ ID NO:3 binds to any of nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), neurotrophin-3 (NT3) or neurotrophin 4/5 (NT4/5) with a binding affinity (Kd) of 5 pM to 5 nM as measured by surface plasmon resonance at 20° C.
5 . The pharmaceutical composition of claim 1 , wherein the polypeptide of SEQ ID NO:3 is formulated for oral, sublingual, buccal, topical, rectal, inhalation, transdermal, subcutaneous, intravenous, intra-arterial, intramuscular, intracardiac, intraosseous, intrasynovial, intradermal, intraperitoneal, transmucosal, vaginal, intravitreal, intra-articular, peri-articular, local or epicutaneous administration.
6 . The pharmaceutical composition of claim 1 , wherein the amount comprises a dose of between 0.3-1.0 mg/kg body weight.